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Abstract
Acylpeptide hydrolase (APEH), one of the four members of the prolyl oligopeptidase class, catalyses the removal of N-
acylated amino acids from acetylated peptides and it has been postulated to play a key role in protein degradation
machinery. Disruption of protein turnover has been established as an effective strategy to down-regulate the ubiquitin-
proteasome system (UPS) and as a promising approach in anticancer therapy. Here, we illustrate a new pathway
modulating UPS and proteasome activity through inhibition of APEH. To find novel molecules able to down-regulate APEH
activity, we screened a set of synthetic peptides, reproducing the reactive-site loop of a known archaeal inhibitor of APEH
(SsCEI), and the conjugated linoleic acid (CLA) isomers. A 12-mer SsCEI peptide and the trans10-cis12 isomer of CLA, were
identified as specific APEH inhibitors and their effects on cell-based assays were paralleled by a dose-dependent reduction
of proteasome activity and the activation of the pro-apoptotic caspase cascade. Moreover, cell treatment with the individual
compounds increased the cytoplasm levels of several classic hallmarks of proteasome inhibition, such as NFkappaB, p21,
and misfolded or polyubiquitinylated proteins, and additive effects were observed in cells exposed to a combination of both
inhibitors without any cytotoxicity. Remarkably, transfection of human bronchial epithelial cells with APEH siRNA, promoted
a marked accumulation of a mutant of the cystic fibrosis transmembrane conductance regulator (CFTR), herein used as a
model of misfolded protein typically degraded by UPS. Finally, molecular modeling studies, to gain insights into the APEH
inhibition by the trans10-cis12 CLA isomer, were performed. Our study supports a previously unrecognized role of APEH as
a negative effector of proteasome activity by an unknown mechanism and opens new perspectives for the development of
strategies aimed at modulation of cancer progression.
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Introduction
In all living cells, proteolysis is essential in the control of many
basic processes, including protein quality control, cell-cycle
progression, signal transduction, apoptosis, and gene expression.
One of the major players in the regulation of intracellular
proteolysis is the ubiquitin-proteasome system (UPS) [1]. This is a
complex enzymatic machine that primarily contributes to the
cytoplasmic turnover of a vast majority of proteins in mammalian
cells and it is tightly controlled by a number of endogenous
regulators. Due to the multiple roles of UPS, it is essential in
eukaryotes and its dysfunction can have deleterious effects in cells
and for the organism as a whole. UPS dysregulation has been
implicated in a number of pathologies such as autoimmune,
neurodegenerative diseases and viral infections, and it is
considered a novel therapeutic target for tackling tumoral diseases
[2–6]. Indeed, protein homeostasis is critically involved in cancer
cell survival thus, targeting the balance between the production
and destruction of proteins mediating cell proliferation, has
become a major focus in cancer research. Accordingly, over the
past decade, several studies have been focused on the development
of specific proteasome inhibitors (PIs), which have relevant
anticancer effects and particularly on those involving in the
repression of nuclear factor-k (NF-k B) signalling, and in the
promotion of apoptosis in transformant cells [7,8].
The first evidence of the pro-apoptotic activity of PIs was shown
in U937 human monoblast cells [9]. In 2003, the PI bortezomib
(VelcadeH or PS341) has been approved by the Food and Drug
Administration for the treatment of multiple myeloma, which
confirmed the efficacy of PIs in blocking cancer progression.
However, like other PIs, bortezomib has several relevant adverse
events [10,11] and, at present, increasing research efforts are
aimed at reducing these negative side-effects through the use of
inhibitors with reversible and time-limited binding activity and
increased bioavailability. Recent studies have suggested that some
fatty acids are able to disrupt the chymotrypsin (CT)-like
proteasome activity. Among these, the two major isomers of
conjugated linoleic acid (CLA), cis9-trans11 CLA (c9t11-CLA) and
trans10-cis12 CLA (t10c12-CLA), have shown pro-apoptotic
activities in a number of cancer cell lines [12] and strong
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although the mechanisms are yet poorly understood, their ability
to inhibit the proteasome activity in vitro [14] suggests that this
complex enzyme could be their ultimate target.
Acylpeptide hydrolase (APEH; also known as acylaminoacyl
peptidase or oxidised protein hydrolase) is one of the four
members of the prolyl oligopeptidase class (POP, clan SC, family
S9); it catalyses the removal of N-acylated amino acids from
acetylated peptides and has been recently recognised as having a
role in the coordinated protein-degradation machinery in Cos-7
cells [15], and in the modulation of cancer progression [16].
On this background, we have investigated the molecular
mechanisms that underlie the interrelationship between APEH
and the proteasome, and their eventual regulation by natural or
synthetic compounds including peptides reproducing the reactive
site loop (RSL) of an archaeal APEH inhibitor (SsCEI, Sulfolobus
solfataricus chymotrypsin-elastase inhibitor) [17], and the c9t11-CLA
and t10c12-CLA isomers. Two molecules that selectively inhibit
APEH and induce, in parallel, a down-regulation of proteasome
activity have been identified. Moreover, a direct correlation
between APEH inhibition and proteasome down-regulation has
been established using a specific APEH siRNA probe. A molecular
docking analysis has been also carried out to predict the CLA-
enzyme binding sites. Therefore, this study shows that proteasome
functions can be upstream regulated by APEH, and that inhibition
of APEH activity appears to be an important event in controlling
the proteasome dysfunction associated with pathological condi-
tions, opening new important and challenging perspectives for the
development of novel strategies in cancer therapy.
Results and Discussion
Peptide design and characterisation
The recent identification and characterisation of an endogenous
inhibitor protein of APEH in S. solfataricus (SsCEI) [17,18], was
the starting point for the present study and the S. solfataricus
APEH (APEHSs) was used, in a first instance, as a model protein
for molecular investigation. On the basis of the RSL of SsCEI, a
set of four peptides, differing in size and nature at their P1 site,
were designed and synthesized. Peptides SsCEI 1 and SsCEI 2
correspond to residues 119–134 and 123–134 of the SsCEI
protein, respectively, and include the P1-P91 (L126-E127) binding
site which is reportedly involved in protease inhibition (Figure S1).
The shorter variant (SsCEI 2), starting with the N-terminus of
RSL, was designed to minimise peptide length while maintaining
intact the RSL binding site. Two further peptides were projected,
SsCEI 3 and SsCEI 4, to replace the P1 residue Leu with Ala,
which is the preferred amino acid in the substrates of mammalian
APEHs. The sequences of these peptides are reported in Table 1.
Amidation at the C-terminal end was introduced to mimic the
amino acid stretch within the protein backbone, whereas the
amino termini of peptides were not acetylated to prevent substrate-
like effects when in contact with APEH. Peptide structures within
SsCEI protein inhibitor are predicted to be random/extended, as
they have to be free in adopting the best conformation needed to
dock the target proteases. Circular dichroism (CD) spectroscopy
analyses were carried out to obtain information on the secondary
structures of peptides outside the context of the native protein.
Interestingly, the CD spectra measured between the 190 nm and
250 nm demonstrated that, except for SsCEI 4 which was largely
unstructured (Figure S2), these peptides have well defined
secondary structures in water. Specifically, CD spectra of SsCEI
2 and SsCEI 4 at 37uC, despite the single mutation, showed
markedly different profiles, suggesting that the LeuRAla substi-
tution at the P1 site induces significant conformational alterations.
CD spectra of SsCEI 2 featured canonical ‘a-helix’ curves with
surprising fidelity (Figure S2). These data are in agreement with
the role that the RSLs have in the native inhibitor proteins, and
suggest a strong tendency of these peptides to adopt different
conformations following even minimal sequence modifications.
CD spectra were also recorded in the temperature range
between 37uC and 77uC, with increasing temperature steps of
10uC. Under these conditions, SsCEI 2 and SsCEI 3 showed
considerable structural stability, as seen by the poor influence of
temperature on their conformation (Figure S2). SsCEI 1 was not
examined due to its poor stability in aqueous solution at the
concentrations required for these analyses. These findings indicate
that, in our model, the backbone architecture of the inhibitory
loop is imposed by its specific amino acid sequence, and that the
protein scaffold does not constrain the conformation of the RSL.
Given the relevant contents of b-sheet structures observed in
SsCEI 2 and SsCEI 3, we next investigated the oligomerization
properties of these peptides to exclude the occurrence of
macroscopic aggregates. For this purpose, 100 mM solutions of
peptides SsCEI 2, SsCEI 3 and SsCEI 4 were analysed by size-
exclusion chromatography, and their apparent molecular masses
were extrapolated from a calibration curve. As shown in Table 1,
SsCEI 2, SsCEI 3 and SsCEI 4 were essentially monomers,
suggesting that the secondary structures detected by CD were not
a result of non-specific self-association, but seemed to be an
intrinsic property of the peptides.
APEHSs is specifically and efficiently inhibited by SsCEI 2
and t10c12-CLA isomer
Preliminary experiments were aimed at investigating the
possible interaction/inhibition between APEHSs and the peptides
SsCEI 2, SsCEI 3 and SsCEI 4. Inhibition analyses were
performed by pre-incubating the enzyme with increasing amounts
Table 1. Synthetic peptides used in this study.
Peptide Theoretical mass value (Da) Measured mass value (Da±SD) P1 P91
SsCEI 1 1818.12 n.d. YAIDTILL EIKNINAD
SsCEI 2 1355.61 19616265 TILL EIKNINAD
SsCEI 3 1766.04 20126150 YAIDTILA EIKNINAD
SsCEI 4 1313.53 1986628 TILA EIKNINAD
Peptides were synthesized with a free amino group at the N-terminus and an amidic group at the C-terminus. The apparent MWs of SsCEI peptides were determined by
gel filtration chromatography. The calibration curve (R2=0.995) was obtained using a set of synthetic peptides. Data reported are the result of three independent
determinations.
doi:10.1371/journal.pone.0025888.t001
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tions (IC50) were determined. The calibration curve for SsCEI 2
followed a hyperbolic pattern with an IC50 value of 9.861.0 mM
as calculated using Ac-Leu-pNA as reporter substrate; however, in
the presence of SsCEI 3 and SsCEI 4 no detectable decrease in the
APEHSs activity was observed (Figure 1A). Therefore, APEHSs
interacts with and is inhibited only by SsCEI 2 which has a Leu on
the P1 site, suggesting that the residue on this position has a major
role in the recognition with the target protease. Moreover, among
the fatty acids tested, only the t10c12-CLA isomer was able to
dose-dependently reduce APEHSs activity with an IC50 value of
8062.0 mM, whilst no significant modulatory effect was observed
using c9t11-CLA isomer (Figure 1B). Notably, APEHSs activity
followed a Michaelis–Menten kinetic, both in the absence and in
the presence of SsCEI 2 but only the Michaelis constant (Km) was
affected by increasing concentrations of substrate, suggesting that
SsCEI 2 behaved as a competitive inhibitor. It was confirmed by
plotting the data according to the Lineweaver–Burk equation (data
not shown), which allowed the calculation of a Ki value for SsCEI-
2 of 1.0060.02 mM. In contrast, in the presence of increasing
amounts of t10c12-CLA isomer, only the Vmax of APEHSs was
affected, indicating a non-competitive inhibition mechanism for
t10c12-CLA, with a Ki value of 140620 mM.
Mammalian APEHs are inhibited by SsCEI peptides and
t10c12-CLA
The inhibition activity of SsCEI peptides was also assessed using
mammalian APEHs purified from both porcine liver and human
colon carcinoma intestinal cells (Caco-2). These two enzymes
share more than 90% sequence identity, as calculated by the
ClustalWalgorithm(http://www.ebi.ac.uk/Tools/msa/clustalw2/).
Ac-Ala–pNA was again used as the preferential substrate for these
mammalian APEHs. As shown in Figure 1C, both SsCEI 2 and
SsCEI 4 dose-dependently decreased porcine APEH activity,
although to different extents (IC50 values were 142630 mMa n d
84616 mM, respectively). Comparable IC50 values were obtained
using human APEH (data not shown). Moreover, the affinity of
SsCEI 4 towards porcine APEH was revealed by a Ki value of
4.060.8 mM, as determined by the Lineweaver-Burk plot, which
also showed that SsCEI 4 is a competitive inhibitor of this enzyme
(Figure 1E). The greater efficacy of SsCEI 4 over SsCEI 2, can be
ascribed to the preference for an Ala residue, with respect to leucine,
at the P1 site, assuming that the SsCEI–APEH association occurs in
a substrate-like manner. Data also suggested that the additional N-
terminal residues in SsCEI 3 (Table 1), negatively affected the
inhibition capacity towards both APEHSs and mammalian APEH
(Figure 1A, C).
Next, the modulatory effects of CLA isomers on porcine APEH
were investigated. The dose-dependent reduction of enzyme
activity followed a hyperbolic pattern in the presence of t10c12-
CLA isomer with an IC50 value of 105623 mM (Figure 1D),
whilst c9t11-CLA was ineffective. In addition the Ki of t10c12-
CLA towards porcine APEH was 140620 mM and the Line-
weaver-Burk plot revealed a non–competitive inhibition mecha-
nism. This is the first evidence of a direct inhibition of APEH by a
CLA isomer.
SsCEI 4 and t10c12-CLA are selective, time-dependent
and non covalent APEH inhibitors
The selectivity of SsCEI 2 and SsCEI 4 for porcine APEH
(hereafter APEH) were analysed in biochemical assays using
a panel of eukaryotic serine proteases comprising trypsin,
a-chymotrypsin, elastase, carboxypeptidase Y, subtilisin and
thrombin. Results showed that SsCEI 4 has no detectable effects
on the proteases tested. In contrast, SsCEI 2 displayed an
inhibition activity towards bovine a-chymotrypsin. The inhibition
curve also followed a hyperbolic pattern with increasing SsCEI 2
concentrations, and gave an IC50 value of 21.966.4 mM (Figure
S3). To further examine the SsCEI 4 specificity towards APEH, its
inhibition activity was determined in a reaction mixture containing
the entire set of proteases reported above. Under these conditions
the inhibition efficiency and the Ki of SsCEI 4 towards APEH
were comparable to those measured in the presence of the APEH
alone (data not shown).
To investigate the molecular inhibition mechanisms of SsCEI 4
and t10c12-CLA, time-dependent experiments were carried out.
Of note, SsCEI 4 and t10c12-CLA inhibited APEH (100% and
43%, respectively) only after pre-incubation with the enzyme for at
least 20 min, suggesting that they behave as time-dependent
inhibitors. Moreover, to exclude the formation of adducts or
degradation products between SsCEI 4 and its protease target
APEH, we analysed the incubation mixtures by reverse-phase
HPLC chromatography. The lack of new peaks in the HPLC
chromatogram and invariability of peak area suggested that
neither peptide degradation nor covalent binding with APEH
occurred under the assay conditions (Figure S3). Data thus
indicated that SsCEI 4 is a highly selective, time-dependent and
non covalent inhibitor of APEH.
Proteasomal degradation of the cystic fibrosis
transmembrane conductance regulator (CFTR) mutated
protein is prevented by SsCEI 4 and t10c12-CLA
The enzymatic stability of SsCEI 4 in 10% FBS was evaluated
as previously reported [19] and the peptide was completely stable
for at least one week under the assay conditions (data not shown).
In light of a recently proposed cooperative role for the APEH–
proteasome system in the control of protein turnover [15], we
hypothesised that APEH could be used as a target to indirectly
control/modulate proteasome functions. To support this idea, we
conducted in vitro experiments using the selected APEH
inhibitors (SsCEI 4 or t10c12-CLA) on the Baby Hamster
Kidney (BHK) cell line stably expressing a mutant protein of the
cystic fibrosis transmembrane conductance regulator (CFTR),
known as DF508 CFTR-3HA (hereafter called CFTR-M),
bearing the deletion of Phe508, one of the most common
modification in patients with cystic fibrosis. Many of the
mutations in the CFTR gene that cause cystic fibrosis interfere
with the folding and biosynthetic processing of CFTR molecules
in the endoplasmic reticulum. Specifically, some mutations,
including the common DF508, decrease the efficiency of CFTR
folding, reduce the probability of its dissociation from molecular
chaperones, and largely prevent its maturation through the
secretory pathway to the plasma membrane. These mutant
CFTR molecules are rapidly targeted for proteolysis via the UPS
[20–22].
Accordingly, BHK and human bronchial epithelial cells
(CFBE41o-DF) expressing CFTR-M were used in this study as a
model system to confirm the role of APEH in the coordinated
protein-degradation machinery, and steady-state levels of the core-
glycosylated CFTR-M form (140 kDa) were evaluated by
immunoblot analysis. Remarkably, the SsCEI 4 peptide and the
t10c12-CLA isomer efficiently prevented degradation of CFTR-M
at the time intervals considered (24 h and 48 h). As a fact,
exposure of BHK cells to 100 mM SsCEI 4 for 48 h or to 100 mM
t10c12-CLA for 24 h induced a marked increase of CFTR-M
levels (twenty- and five-fold, respectively) (Figure 2A, B, C),
without any cytotoxic effects (data not shown). In addition, a dose-
APEH Mediated Inhibition of Proteasome
PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e25888Figure 1. Kinetic analysis of SsCEIs and CLA isomers towards APEHs. Binding of increasing concentrations of the SsCEI peptides (A), and CLA
isomers (B) to APEHSs. Binding of SsCEI peptides (C), and t10c12-CLA (D) to porcine APEH. The hyperbolic curves indicate the best fits for the data
obtained, with IC50 values calculated from the graphs. Inhibition kinetics analyses with porcine APEH (0.5 nM) at increasing SsCEI 4 concentrations:
100 mM (triangles) and 150 mM (squares) (E). Similarly, inhibition kinetics by increasing t10c12-CLA concentrations: 50 mM (squares) and 100 mM
(triangles) (F). Enzyme incubated without inhibitors were used as control (diamonds) (E, F). The inhibition constants, Ki, were determined by the
Lineweaver–Burk equation for competitive and non-competitive inhibition, respectively.
doi:10.1371/journal.pone.0025888.g001
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was observed upon 48 h of incubation (similar data on APEH and
proteasome activities were measured after 24 h cell exposure) with
both compounds, as shown in Figure 2D, E consistent with the
immunoblot results.
Finally, siRNA technique was used to directly correlate APEH
to the protein degradation processes via UPS. For this purpose, the
accumulation of CFTR-M was evaluated in CFBE41o-DF cells
following transfection with APEH siRNA. As shown in Figure 2F,
APEH siRNA-transfected cells exhibited a considerable reduction
Figure 2. Analysis of the CFTR-M protein accumulation in BHK cells treated with the SsCEI 4 and t10c12-CLA and in APEH siRNA
transfected CFBE41o-DF cells. Representative Immunoblots and associated densitometric analysis for cytosolic CFTR-M accumulation in BHK cells
following 24 h and 48 h exposure to 50 mM or 100 mM SsCEI 4 (A), and to 50 mM or 100 mMt 10c12-CLA (B). Bands were quantified using densitometric
analysis and normalized against a-tubulin. The values were expressed as average fold increase as compared to untreated culture (C). APEH activity
was measured in BHK cells incubated with 50 mM and 100 mM SsCEI 4 (white bars) or t10c12-CLA (grey bars) for 48 h (D). CT-like proteasome activities
were measured in BHK cells incubated with 50 mM and 100 mM SsCEI 4 (white bars) or t10c12-CLA (gray bars) for 48 h (E). Untreated cultures were
used as controls (black bars); the data are expressed as means6SD. *Significantly different (P,0.005) from the control (D, E). Representative
Immunoblots of APEH and CFTR-M accumulation in CFBE41o-DF cells transfected with APEH siRNA. A scrambled, non-targeted siRNA, was used as
negative control and a-tubulin was used as loading control (F).
doi:10.1371/journal.pone.0025888.g002
APEH Mediated Inhibition of Proteasome
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(eight-fold, data not shown) (Figure 2F), in contrast to cells
transfected with a not specific siRNA which displayed basal levels
of APEH and neglectable level of CFTR-M. Therefore, APEH
can be seen as an alternative target, whose inhibition by
competitive as well as non-competitive inhibitors is accompanied
by a parallel down-regulation of proteasome activity through a yet
unknown mechanism.
SsCEI 4 and t10c12-CLA down-regulate APEH and
proteasome activities in cancer cells
Proteasome inhibition represents a validated, although chal-
lenging, anticancer approach. However, to prevent the adverse
effects deriving from indiscriminate cell death, inhibition of the
proteasome needs to be tightly controlled or selectively induced in
cancer tissues. Therefore, the concept that proteasome activity
could be decreased via APEH inhibition was investigated in a
cancer cell line. To this end, differentiated human colon
carcinoma Caco-2 cells were treated with SsCEI 4, t10c12-CLA
or with a specific PI (MG132) for 48 h. As shown in Figure 3A,
SsCEI 4 and t10c12-CLA markedly reduced APEH activity in a
dose-dependent manner, reaching their maximum effect at
200 mM, where enzyme activity was decreased by 70% and
50%, respectively. Under the same conditions MG132 treatment
had no detectable effects.
We next examined the inhibitory effects of SsCEI 4 and t10c12-
CLA on the CT-like proteasomal activity in Caco-2 cells and in
cell-free assays. In these latter experiments, partially purified
proteasome fractions from Caco-2 cells were used instead of the
commercially available 20S proteasome or immunoproteasome.
Indeed, it has been reported that in neoplastic cell lines the CT-
like proteasomal activity, as well as the sensitivity to different PIs, is
greatly influenced by the highly variable proteasome subunit
composition [23].
Therefore, cell exposure to SsCEI 4 and t10c12-CLA, produced
a dose-dependent decrease (up to 45% of the residual activity) of
the CT-like proteasome activity with respect to the untreated
cultures, whereas partially purified proteasome was not affected by
these compounds (Figure 3C, D), thus confirming that it is not
directly targeted by these inhibitors.
Next, we evaluated the effects of SsCEI 4 and t10c12-CLA
treatment on the activation of caspases. As shown in Figure 3B,
Figure 3. Down-regulation of the proteasome/APEH enzyme system by the SsCEI 4 and t10c12-CLA in Caco-2 cells. APEH activity was
measured in Caco-2 cells incubated with 50 mM, 100 mM and 200 mM SsCEI 4 (white bars) or t10c12-CLA (gray bars) for 48 h (A). Proteasomal CT-like
activity was measured in cell-free system (a partially purified proteasome fraction from differentiated Caco-2 cells, gray bars) and in Caco-2 cells
(white bars) treated with increasing concentrations of SsCEI 4 (C) or t10c12-CLA (D). Caspase-3 activities and LDH release were measured upon 48 h
incubations of Caco-2 cells with increasing concentrations of SsCEI 4 (white bars) and t10c12-CLA (striped grey bars) (B). The cytotoxic effect of the
different treatments was evaluated by measuring the LDH release in the culture media (B insert). Cell-free protein mixtures, or Caco-2 cell cultures,
treated with DMSO alone (black bars) or with MG132 (10 mM) (striped black bars) were used as positive controls. The data are expressed as
means6SD. *Significantly different (P,0.005) from respective controls.
doi:10.1371/journal.pone.0025888.g003
APEH Mediated Inhibition of Proteasome
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increasing doses of either SsCEI 4 or t10c12-CLA. This was not
associated with any cytotoxic effect even at the highest
concentration (200 mM), as indicated by the lactate dehydrogenase
(LDH) activity levels which remained comparable to those of
controls (Figure 3B insert).
Therefore, our results, consistently with the reporting coordi-
nated functions of proteasome and APEH in protein turnover
[15], add the relevant information that proteasome modulation
could occur via a complex pathway which has APEH like an
important and regulative factor. Moreover, since APEH activity is
not influenced by cell treatment with the specific PI MG132
(Figure 3A), proteasome modulation should be hierarchically
down-stream of APEH inhibition. This view is also corroborated
by the observation that APEH and proteasome seem to have no
direct interactions, as they are distinctly eluted from gel filtration
columns loaded with protein extracts obtained from SsCEI 4-
treated or untreated Caco-2 cells (Figure S4). Further investiga-
tions aimed at a better understanding of the molecular mechanism
underlying the proteasome inhibition by APEH are currently in
progress.
The combined use of SsCEI 4 and t10c12-CLA improves
the inhibition of proteasome activity, triggers apoptosis
and increases the level of UPS substrates in Caco-2 cells
To finally confirm the reliability of the APEH-mediated strategy
to affect UPS activity, several readouts were evaluated in
differentiated Caco-2 cells treated with SsCEI 4 and t10c12-
CLA, alone or in combination. Caco-2 cells were incubated for
48 h with SsCEI 4, t10c12-CLA (200 mM), or an equimolar
mixture (100 mM each) of both compounds. The commercially
inhibitors of APEH (ebelactone) or the proteasome (MG132) were
used as positive controls.
Cell exposure to SsCEI 4 or t10c12-CLA saw 40% reduction in
the proteasomal CT-like activity, with a more marked decrease
(about 73%) resulting from their combined use (Figure 4A). A
similar behaviour was observed when APEH activity was
monitored (data not shown), which supports the hypothesis of an
additive effect (combination index; CI=1) [24] produced by
SsCEI 4 and t10c12-CLA on the target protease. However, due to
the difficulties in the setting-up the large number of variables
which possibly affect the formation of enzyme–inhibitor-substrate
complexes, we were unable to reproduce the additive effects on the
proteasome or APEH activities in cell-free assays.
To evaluate the pro-apoptotic effects arising from cell exposure
to a mixture of SsCEI 4 and t10c12-CLA, we measured caspase-3
and caspase-8 activities as these enzymes have been reported to be
essential for the proteasome-induced apoptosis cascade [6,25].
Specifically, caspase-3 was significantly increased by SsCEI 4 or
t10c12-CLA (about two-fold in both cases; P,0.01), with a further
improvement produced by their combination (about four-fold), in
comparison to untreated cultures. Although caspase-8 activity was
less intense, it showed a profile similar to that of caspase-3, further
supporting the view that cell death occurs by an apoptotic
mechanism (Figure 4B). These data are in agreement with the
well-established association between proteasomal inhibition and
apoptosis induction, and confirm the additive effects produced by
using a mixture of SsCEI 4 and t10c12-CLA on the caspase
cascade in cancer cells. Notably, the toxicity resulting from the
APEH-mediated inhibition of proteasome activity, as indicated by
the treatment with SsCEI 4, t10c12-CLA or ebelactone, was
significantly lower than that observed in culture incubated with
MG132 (Figure 4B insert).
Moreover, the immunoblot analysis, showing that the levels of
APEH in cells were not affected by any of these treatments, clearly
indicated that the APEH down-regulation resulted from an
enzyme inhibition process, rather than a reduction in protein
expression. Cell exposure to SsCEI 4 and t10c12-CLA, alone or in
combination, produced an increase of well-known proteasome
substrates (p21Waf1 and NF-kB, two-fold or four-fold, respective-
ly; Figure 4C, D). These findings are consistent with the idea that
the relationship between apoptosis and the accumulation of
damaged or short-lived regulatory proteins has a prominent role in
controlling the homeostasis of cancer cells [22]. Cytoplasmic
increase of NF-kB levels is indeed regarded as a major hallmark of
apoptotic cells, since NF-kB nuclear translocation, following I-kB
degradation by UPS and gene transcription, is a well-established
mechanism of cell growth. Proteasome inhibition in cancer cells
leads to a reduced rate of I-kB degradation, and to a longer
persistence of NF-kB in the cytoplasm [26,27]. In the same way,
accumulation of p21Waf1, a negative regulator of the cell division
cycle, is a direct evidence of increased apoptosis and of reduced
proteasome activity, since it has been reported that its degradation
occurs through N-terminal as well as internal lysine ubiquitinyla-
tion [28].
Polyubiquitinylated proteins are normally degraded by the
cellular proteasomes, and down-regulation of proteasome activity
has been shown to substantially suppress bulk intracellular protein
turnover [29]. As evidenced in Figure 4E, following incubation
with SsCEI 4, t10c12-CLA (alone or in combination), ebelactone
or MG132, we detected in cell extract the presence of high-
molecular-mass immunoreactive species (66 kDa to 160 kDa)
which are absent in untreated cultures. These signals are indicative
of polyubiquitin conjugates in the treated cells, confirming that
these compounds deregulate UPS activity in cancer cells.
As a whole, our in vitro results demonstrate that APEH
inhibition by SsCEI 4 and t10c12-CLA treatments is associated
with increased levels of the typical markers of proteasome
inhibition without any cytotoxic effect. Although pro-apoptotic
activities of CLA mixtures and their ability to induce an increase of
the cytoplasm levels of NF-kB and p21Waf1 have been previously
reported [30,31], to our knowledge this is the first study showing
that their effects are mediated, at least in part, by the APEH/
proteasome system, suggesting a possible mechanism by which
CLA isomers exert their anticancer activity.
Putative APEH binding site for t10cis12-CLA isomer
In light of these outcomes, APEH inhibition represents a novel
strategy to regulate proteasome activity, with potential applications
in biomedical fields. Knowledge of the enzyme–inhibitor binding
sites at the molecular level is pivotal for our understanding of the
underlying mechanisms, as well as for the design of novel and
more efficient inhibitors. In a previous work [17], the structural
model of the inhibition complex APEHSs-SsCEI protein corrob-
orated by mutagenesis studies, indicated an involvement of the
SsCEI RSL in the interaction with the active site of the enzyme
target. Therefore, it is conceivable to assume that the competitive
inhibition of APEHSs by SsCEI 4 peptide occurs through a similar
binding-mode.
The surprising down-regulation of APEH by t10c12-CLA and
the finding of additional non-competitive APEH binding pockets
apart from the active site, prompted us to undertake a molecular
modelling study to look for potential APEH-CLA binding sites.
Protein-fatty acid docking analyses were carried out starting from
the previously reported structural model of APEHSs [17], herein
used for the biochemical investigation. The APEHSs 3D model,
built on the X-ray structure of APEH from Aeropyrum pernix
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hydrolase catalytic domain with the (Ser-Asp-His) catalytic triad,
covered by a central tunnel of an unusual b-propeller domain.
Docking calculations were performed by using the AutoDock
simulation package[33]. Thedocked conformations oft10c12-CLA
suggested two putative binding modes that were characterised by
different anchoring points for the carboxylate group of the CLA
isomer: the positively charged side-chains of either R62 or R507.
However, the binding involving the residue R507 appeared to be in
conflict with the non-competitive inhibition mechanism indicated
by the experimental data, as R507 belongs to the active site of
APEHSs [17]. Thus we did not consider this binding approach
further. binding of t10c12-CLA involving R62 residue of the
enzyme is in agreement with the non-competitive mechanism of
inhibition resulting from cell-free assays. In this case, t10c12-CLA
occupies the b-propeller tunnel, eventually obstructing the passage
of the substrateand/orthe product (Figure 5).Details of the binding
mode involving R62 are shown in Figure 6: t10c12-CLA
carboxylate group interacts with the side-chains of R62 and S273
of APEHSs, while the long hydrophobic carbon tail of t10c12-CLA
is stabilised by van der Waals interactions with some of the
hydrophobic residues that line the b-propeller tunnel of APEHSs.
Figure 4. Evaluation of proteasome inhibition markers in Caco-2 cells incubated with SsCEI-4 and t10c12-CLA, alone or in
combination. Caco-2 cells were treated (48 h) with 10 mM MG132 (MG), 100 mM ebelactone (Ebel), 200 mM SsCEI 4 (S4), t10c12-CLA (t10), or with a
mixture of both (t10+S4). Cells exposed to DMSO alone were used as the controls (black bar). The data are expressed as means6SD. *Significantly
different (P,0.005) from the control (A). Caspase-3 (white bars) and caspase-8 (grey bars) activities measured as fold increase in comparison to
untreated cells (B). The cytotoxic effect of the different treatments was evaluated by measuring the LDH release in the culture media (B insert).
Representative immunoblots of the expression of p21Waf1, NF-kB, and APEH in Caco-2 cell exposed for 48 h to MG, Ebel, S4, t10 or with a mixture of
both (t10+S4) (C). Data on Western blot analysis are expressed as the density ratio of target to control (b-actin) in arbitrary units. The values were
expressed as average relative intensity as compared to untreated cultures and expressed as means6SD of measurements performed in triplicate (D).
Protein ubiquitinylation in Caco-2 cell exposed for 48 h to MG, Ebel, S4, t10 or with a mixture of both (t10+S4) (E, upper panel). Upon the
immunodetection, the membrane was stained with Coomassie blue. The lane loaded with molecular mass markers [MW kDa] was shown (lower
panel).
doi:10.1371/journal.pone.0025888.g004
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analysis shares common characteristics with the fatty-acid-binding
proteins (FABP) [34,35]. X-ray structural studies have shown that
the fatty acid molecule binds to the relatively large FABP inner
cavity, and is anchored to a positively-charged arginine residue
and a polar amino acid (usually serine or threonin), with the
hydrophobic tail again stabilised by van der Waals interactions
with hydrophobic residues.
The lack of structural information and the difficulty to predict a
sufficiently accurate 3D model for any mammalian APEH have
prevented us from performing modelling studies on mammalian
APEHs. However the functional properties indicate significant
similarity between mammalian and archaeal APEHs, showing that
both are inhibited by SsCEI 4 peptide in a competitive manner
(Figure 1E) or by t10c12-CLA through a non-competitive
mechanism (Figure 1F), with comparable Ki values. Therefore,
we hypothesise that the enzymes from archaeal and mammalian
sources could share some common features in their modes of
interaction with these inhibitors suggesting that APEHSs can be
used as an initial model system for the early design of novel
inhibitors of mammalian APEH.
Conclusions
Proteasome is an abundant multi-enzyme complex that provides
the main pathway for the protein turnover or the elimination of
misfolded and aggregated proteins. As such, it controls the levels of
proteins involved in cell-cycle progression and apoptosis in normal
and malignant cells, and has become an important therapeutic
target in anticancer therapies. A large number of specific PI
molecules have been developed to date [36], but despite their
indisputable efficacies all of these suffer for negative side-effects.
These events represent the major drawback of impairing the
activity of a target largely involved in physiological processes. For
these reasons, several studies have suggested that the targeting of
functionally related, up-stream or down-stream proteasome
effectors [29], can be an alternative and a safer way to recover
proteasome dysfunction associated with pathological conditions
[29,37,38].
In this study we showed for the first time that, by using a set of
selected APEH inhibitors, proteasome activity can be regulated
through an APEH-mediated mechanism which represents a novel
strategy to control UPS functions. Beside these findings, we
demonstrated that the stable, selective and non toxic inhibitors of
APEH (a synthetic peptide and a CLA isomer) are able to produce
a noticeable down-regulation of UPS activity in cells. Moreover,
Figure 5. Binding mode of the t10c12-CLA with APEHSs. Binding mode suggested by docking analysis for t10c12-CLA (blue; ball-and-stick mode)
with APEHSs (cartoon representation; green, left). Protein residues involved in stabilising the interactions with the carboxylic group of the t10c12-CLA
are represented as sticks. The Ser-Asp-His catalytic triad residues are shown as black lines; R507 is shown in yellow. (right) View rotated 90u along the
x-axis (the horizontal axis parallel to the image plane).
doi:10.1371/journal.pone.0025888.g005
Figure 6. Suggested binding site on APEHSs.by docking
analysis for the t10c12-CLA (blue; ball-and-stick mode) isomer.
The relevant APEHSs residues are shown in ball-and-stick representation.
doi:10.1371/journal.pone.0025888.g006
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more potent inhibitors, with potential applications as anticancer
and anti-inflammatory agents. In addition, the synergistic effects
resulting from their combined use strongly suggest that chimeric
compounds, including competitive and non-competitive inhibitors,
with increased specificity and enhanced activity, can be investi-
gated and developed.
APEH has been postulated to serve as a key regulator of N-
terminally acetylated proteins [39] but the biological effects of
disrupting APEH has not been completely understood. As more
than 80% of proteins in human cells are N-terminal acetylated
[40–42] and protein acetylation is implicated in a variety of
essential cellular pathways [43], it is thus likely feasible that APEH
is involved in these processes.
As reported in previous studies, proteasome and APEH act
cooperatively in protein turnover [15,44], although the biochem-
ical mechanisms remain to be clarified. In this regard, in contrast
to the general idea that N-terminal acetylation protects from
degradation, in certain proteins some sequences which include
acetyl groups at the N-terminus were recently found to be involved
in degradation signals [45,46]. On the basis of our preliminary
results, a direct interaction between APEH and proteasome might
be excluded, whereas the hypothesis that APEH can activate or
stabilise the proteasome by uncovering the N-tail of a yet unknown
negative effector protein cannot be ruled out. Of note, we showed
that whereas APEH inhibition triggered an impairment of the
proteasome activity, its selective inhibition did not affect APEH
functions, likely suggesting that APEH could be an up-stream
modulator of the proteasome. Studies aimed at achieving a better
understanding of the mechanism/s responsible for the APEH-
mediated down-regulation of proteasome and at the evaluation of
APEH inhibitors in animal cancer model are currently in progress.
Materials and Methods
Reagents
Pure c9t11- and t10c12-CLA isomers and caspase-3 and -8
fluorometric Assay Kits were purchased from Sigma-Aldrich.
DMEM/F12, DMEM, L-glutamine, penicillin-streptomycin and
FBS were from Gibco-BRL. Porcine liver APEH was obtained by
Takara. Chemicals of the highest purity were from Sigma-Aldrich
or Calbiochem.
Peptide design, synthesis and characterisation
The peptides were prepared as amidated derivatives by solid-
phase synthesis (synthesis scale, 0.1 mmoles), following standard
Fmoc/tBu protocols [47]. A rink amide resin (substitution,
0.57 mmol/g) and amino acid derivatives with standard protection
were used in all of the syntheses. Cleavage from the solid support
was performed by treatment with a trifluoroacetic acid (TFA)/tri-
isopropylsilane/water (90:5:5, v/v/v) mixture for 90 min at room
temperature. The crude peptides were precipitated in cold ether,
dissolved in a water/acetonitrile (1:1, v/v) mixture and lyophilised.
The peptides were purified by reverse-phase HPLC using a semi-
preparative 561 cm ID C18 monolythic Onyx column, applying a
linear gradient of 0.05% TFA in acetonitrile from 10% to 70%
over 8 min at a flow rate of 15 mL/min. Peptide purity and
identity were confirmed by liquid chromatography–mass spec-
trometry analysis.
Gel filtration analysis of synthetic peptides
Gel filtration chromatography was performed on a BioSep
SEC-S2000 column equilibrated with 50 mM phosphate buffer
pH 6.8, at a flow rate of 1.0 mL/min. A standard curve was built
using a set of synthetic peptides with molecular weights between
1.500 amu and 2.500 amu. For this purpose, peptide aliquots
were injected onto the column and a plot of KD versus log10
molecular weights (MW) was obtained, where KD=(Ve-Vo)/(VT-
Vo), Ve is the elution volume of the sample, and VT and Vo are
the total and void volumes of the column, respectively.
Circular dichroism spectroscopy
CD spectra were obtained on a Jasco J-715 spectropolarimeter
with 400 mL of 8.0610-7 M protein in 5 mM Tris–HCl pH 7.5.
Hellman quartz cells of 0.1-cm-path length were used in the far
UV (190–250 nm). The temperature of the sample cell was
regulated by a PTC-348 WI thermostat and thermal CD was
performed from 250 to 195 nm by raising the cell temperature
from 37uCt o7 7 uC. The thermal CD spectra were signal-averaged
by combining three scans and the baseline was corrected by
subtracting a buffer spectrum. The samples were then cooled back
to 37uC to monitor the final folding of the peptides.
Purification of APEHs and proteasome
APEH from Sulfolobus solfataricus was purified as previously
reported [17]. Partial purification of human APEH and proteasome
was carried out from protein extracts of Caco-2 cell. Briefly, protein
extracts (500 mg) were fractionated by gel filtration chromatography
on a Superdex 200 PC 3.2/30 column connected to a SMART
System (Pharmacia) equilibrated in buffer 50 mM Tris-HCl,
pH 7.5, 100 mM NaCl, at 0.1 mL/min. The eluted fractions were
assayed using the specific substrates for APEH and the proteasome.
The active fractions were collected and used for further analysis.
Enzyme assays
Porcine liver APEH activity was measured spectrophotometri-
cally using the chromogenic substrate acetyl-Ala-pNA (Bachem).
The reaction mixture (1 mL) containing pure APEH (38 ng) or an
appropriate amount of cell extract in 50 mM Tris-HCl buffer
pH 7.5 (Tris Buffer), was preincubated at 37uC for 2 min. Then,
1 mM acetyl-Ala-pNA was added and the release of p-nitroanilide
(e410=8800 M-1 cm-1) was measured by recording the absor-
bance increase at 410 nm on a Cary 100 Scan (Varian) UV/Vis
spectrophotometer, equipped with a thermostated cuvette com-
partment. APEH activity was expressed in IU. The APEHSs
activity was measured using acetyl-Leu-pNA (0.1 mM) (Sigma) as
substrate. The reaction mixture (1 mL) containing the appropriate
amount of enzyme in 25 mM Tris-HCl buffer pH 7.5, was
preincubated at 80uC for 2 min. Then, 0.1 mM acetyl-Leu-pNA
was added and the release of p-nitroanilide was measured,
following the standard assay procedure described above.
The synthetic fluorescent substrate N-succinyl-Leu-Leu-Val-
Tyr-7-amido-4-methylcoumarin (N-Suc-LLVT-AMC) was used
for the measurement of the CT-like activity of the proteasome, at a
final concentration of 0.080 mM. The reaction mixture (0.9 mL)
containing appropriate amount of proteasome was preincubated
as above, in Tris buffer. N-Suc-LLVT-AMC was added, and the
release of the fluorescent product (7-AMC) was monitored for
5 min in a Perkin–Elmer LS 50B fluorimeter. The excitation and
emission wavelengths were 380 nm and 460 nm, respectively.
The carboxypeptidase Y, elastase, thrombin, trypsin and
subtilisin activities were also evaluated according to previously
published methods [18].
Enzyme inhibitory assays
Protease inhibitor activities of the SsCEI peptides and the CLA
isomers were carried out using a fixed amount of APEH or
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tively), and increasing the SsCEI and CLA isomer concentrations.
Mixtures were pre-incubated for 30 min at 37uC before the
addition of the substrate, and the enzymatic activities were
followed as described above. Protease inhibitor activities of the
SsCEI peptides and the CLA isomers were determined towards
APEHSs. The protease and increasing concentrations of the
inhibitors were mixed and preincubated for 30 min at 80uC before
the addition of the specific substrate. The residual enzymatic
activity was determined using the assay procedure described
above.
The time-dependent inhibition of SsCEI 4 and t10c12-CLA
towards APEH was assessed. Mixtures containing appropriate
amounts of each inhibitor and of APEH were pre-incubated for
20 min at 37uC; they were then diluted (1:5) into the standard
assay mixture, which contained the substrate only. The enzymatic
activity was followed as described above. Control samples were
prepared by pre-incubating the same amounts of APEH without
the inhibitors and then diluted in the standard assay mixture.
The additive effects elicited by cell exposure to SsCEI 4 and
t10c12-CLA was calculated accordingly to the Chou and Talalay
equation (CI=D1/[(DM)16[fa/(1-fa)]1/m1+D2/[DM26[fa/(1-
fa)] 1/m2) [24].
HPLC analysis of SsCEI peptides incubated with the
target enzyme
The experiments were conducted at 37uC in 50 mM Tris
buffer, pH 7.5. Solutions of SsCEI 4 and porcine APEH were
incubated for up to 2 h at optimal concentrations (4 mM SsCEI 4
and 100 mM APEH) to guarantee a high degree of enzymatic
inhibition. At specific time intervals, 195 mL aliquots were taken,
and the reaction was stopped by addition of 5 mL TFA. The
samples were then analysed directly by reverse-phase HPLC
(Dionex BioLC) on a mBondapak C18 column (3.96300 mm,
Waters), eluted with a linear gradient (0–60% acetonitrile in 0.1%
TFA) at a flow rate of 1 ml/min. Control peptide samples were
incubated in the absence of the purified enzymes and run in
parallel.
Antibodies
The following antibodies were used: anti-APEH antibody (sc-
102311; Santa Cruz Biotechnology); anti-NF-kB/p65 antibody
(Thermo Scientific); anti-p21Waf1 antibody (Exbio); pan Ab-5
anti-actin antibody (clone ACTN05, Thermo Scientific); and
monoclonal antibodies against polyubiquitinylated proteins con-
jugated with horseradish peroxidase (FK2H, Enzo, Life Science).
The DF508CFTR-3HA protein was detected with an anti HA
monoclonal antibody (Covance).
Cell culture
BHK cells stably expressing CFTR-M (kindly donated by Dr.
David Y Thomas, McGill University Montreal Canada) were
cultured in DMEM/F12, 5% FBS, 1 mM L-glutamine, 200 mg/
mL methotrexate, and 100 units/mL penicillin-streptomycin, at
37uC in a humidified 5% CO2 atmosphere. The cells were plated
in 12-well plates, to a confluence of 60% for the 24-h incubations,
and 40% for 48-h exposure to PIs. These treatments were initiated
24-h after the plating of the cells. Phase-contrast images of the cells
were taken just before the lysis of the cells for protein analysis,
using a Lica DM6000 inverted microscope.
Caco-2 cells (ATCC) were cultivated in DMEM supplemented
with 10% FBS, 1 mM glutamine and 100 units/mL penicillin-
streptomycin at 37uC in a humidified 5% CO2 atmosphere. The
cells were studied between passages 12 and 22. The cells were split
using trypsin-EDTA solution and plated in 6-well plates at a
density of 86104 cells/mL and the medium was replaced every 2–
3 days. Under these conditions, the cells reached visual confluence
after 7 days and the differentiated stage two weeks later. The
differentiated cells were incubated for 48 h with the different
substances.
Protein extraction and Western blotting analysis
Following the treatments, the BHK and Caco-2 cells were
washed three times with ice cold phosphate-buffered saline and
collected immediately at 4uC in lysis buffer (1% Triton X-100,
0.1% SDS, 20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.5%
sodium deoxycholate and complete protease inhibitors [Roche]).
The lysates were centrifuged at 10,0006g for 15 min at 4uC. The
protein concentrations in the clear supernatants were determined
(BCA protein assay reagent kit; Pierce) before their use in
enzymatic assays or SDS–PAGE. In brief, for Western blotting,
aliquots were run on SDS-PAGE (8% or 12.5%) and then
electroblotted onto nitrocellulose (Schleicher & Schuell) or PVDF
membranes (Immobilon
TM, Millipore). The membranes were next
incubated with primary antibodies and then with the appropriate
dilution of secondary antibody (1 h at 37uC). At the end of this
time, the immunocomplexes formed were visualised by enhanced
chemiluminescence and autoradiography according to the man-
ufacturer protocol (Amersham Biosciences) and quantified by
densitometric analysis with ChemiDoc XRS (Bio-Rad). Protein
expression data was quantified with Quantity One Software (Bio-
Rad).
Apoptosis assays
The pro-apoptotic ability of the peptides and the CLA isomers
were assayed by measuring the caspase-3 and caspase-8 activities
using fluorometric kits, according to the manufacturer instructions.
These assays were based on hydrolysis of the substrate acetyl-Asp-
Glu-Val-Asp-7-amido-4-methylcoumarin (Ac-DEVD-AMC) or
acetyl-Ile-Glu-Thr-Asp-7-amino-4-methyl coumarin (Ac-IETD-
AMC) by caspase-3 and caspase-8, respectively. The release of
the 7-AMC moiety in protein extracts prepared from the
differently treated cells was evaluated by fluorimetry (excitation
360 nm, emission 460 nm). Their amounts were calculated by
means of a standard curve prepared with pure AMC, and
following normalisation for protein content, the activities were
expressed as nmoles AMC/mg protein/min.
Cytotoxicity assay
The release of LDH was used as the marker for cell toxicity
[48]. The culture supernatants were sampled at the end of the
incubations and centrifuged (4,0006g, 5 min, and 4uC). Aliquots
of the clear supernatant (10 mL) were incubated with 190 mL
reaction buffer (200 mM Tris/HCl, pH 8.0, 0.7 mM p-iodoni-
trotetrazolium violet, 50 mM L-lactic acid, 0.3 mM phenazine
methoxysulphate, 0.4 mM NAD,) for 30 min at 37uC. Absorbance
was measured at 490 nm and the results were expressed as
percentages of total LDH release from control cultures treated
with 1% (w/v) Triton X-100 and calculated as: [(experimental
value - blank value)/(total lysis -blank value)2100].
Docking calculations
The AutoDock (version 4.0) programme package [33] was
chosen to dock t10c12-CLA into the large inner cavity of the
APEHSs enzyme. The previously reported atomic coordinates of
the APEHSs model [17], were used in the calculations. Amber
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PDB2PQR server (http://pdb2pqr-1.wustl.edu/pdb2pqr/). The
ligand coordinates were generated by the PRODRG server
(http://davapc1.bioch.dundee.ac.uk/prodrg/), and subsequently
energy minimised using the Insight II package; atom charges and
active torsions were defined using AutoDockTools. Affinity grids
with dimensions 80680690 points (with spacings of 0.375 A ˚) were
centred approximately in the middle of the enzyme b-propeller
central tunnel and were large enough to cover the entire inner
cavity of the enzyme subunit. The Lamarckian genetic algorithm
and the pseudo-Solis and Wets methods were used for the
conformational search. The maximum number of energy
evaluations was set to 2.56107 and a maximum number of
2.76105 genetic algorithm operations were generated on a single
population of 150 individuals. The operator weights for crossover,
mutation, and elitism were set as the default parameters: 0.80,
0.02, and 1.0, respectively. One hundred runs were performed.
The resultant docked conformations of the ligand were clustered
and ranked according to the default AutoDockTools scoring
function using a RMSD deviation of 3.5 A ˚. The MOLMOL
programme was used for the molecular visualisation and analysis
[49].
Small interfering RNA transfection
The siRNA is purchased from Sigma (siRNAID SA-
SI_Hs01_00240856 and SASI_Hs01_00240857), and CFBE41o-
DF espressing DF508 CFTR were kindly provided by Dr. J. P.
Clancy Department of Pediatrics, the University of Alabama at
Birmingham, Birmingham, AL, USA. CFBE41o-DF cells at
56104 cells/well were cultured over-night on 12-well plates and
transfected 24 h after with APEH siRNA at a final concentration
of 50 nM. using Lipofectamine 2000, according to the manufac-
turer’s instruction. Non-targeting siRNA was used as a negative
control. After 72 hours of transfection, cells are lysed in RIPA
buffer and protein levels were determined by western blotting
Statistical analysis
All data were obtained from triplicate analyses of three different
preparations. Data were presented as means 6S.D. Statistical
analysis and IC50 values were calculated with the SigmaPlot 10.0
software through a non-linear curve-fitting method and using a
simple binding isotherm equation. Groups were compared by
Student’s t test, and P,0.05 was considered as significant.
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